Abstract-To investigate the kinetic parameters of the crossbridge cycle that regulate force and shortening in cardiac muscle, we compared the mechanical properties of cardiac trabeculae with either ATP or 2-deoxy-ATP (dATP) as the substrate for contraction. Comparisons were made in trabeculae from untreated rats (predominantly V1 myosin) and those treated with propylthiouracil (PTU; V3 myosin). Steady-state hydrolytic activity of cardiac heavy meromyosin (HMM) showed that PTU treatment resulted in Ͼ40% reduction of ATPase activity. dATPase activity was Ͼ50% elevated above ATPase activity in HMM from both untreated and PTU-treated rats. V max of actin-activated hydrolytic activity was also Ͼ50% greater with dATP, whereas the K m for dATP was similar to that for ATP. This indicates that dATP increased the rate of crossbridge cycling in cardiac muscle. Increases in hydrolytic activity were paralleled by increases of 30% to 80% in isometric force (F max ), rate of tension redevelopment (k tr ), and unloaded shortening velocity (V u ) in trabeculae from both untreated and PTU-treated rats (at maximal Ca 2ϩ activation), and F-actin sliding speed in an in vitro motility assay (V f ). These results contrast with the effect of dATP in rabbit psoas and soleus fibers, where F max is unchanged even though k tr , V u , and V f are increased. The substantial enhancement of mechanical performance with dATP in cardiac muscle suggests that it may be a better substrate for contractility than ATP and warrants exploration of ribonucleotide reductase as a target for therapy in heart failure. (Circ Res. 2000;86:1211-1217.) Key Words: in vitro motility Ⅲ hypothyroid Ⅲ myosin isoforms Ⅲ contractile kinetics Ⅲ shortening velocity I n both cardiac and skeletal muscles, contraction results from the cyclic interactions between actin and myosin when chemical energy, supplied by hydrolysis of MgATP, is converted into mechanical work, force, and shortening (chemomechanical transduction). Skeletal myosin and actomyosin ATPase activity have been studied extensively in solution, and a detailed picture of the number of steps and rate-limiting processes of the actomyosin ATPase cycle now exists (reviewed in Reference 1). More recently, similar analyses have been conducted in chemically skinned, fast skeletal muscle fibers using measurements of force transients that follow quick length changes; a variety of strong crossbridge inhibitors; or the photolysis of caged compounds such as ATP, ADP, P i , and Ca 2ϩ (reviewed in Reference 2). These studies are necessary to elucidate the chemomechanical transduction pathway, because the orderly array of thin and thick filaments in muscle imposes constraints on actomyosin interactions. The results of these studies have led to detailed models of chemomechanical transduction that suggest the rate-limiting processes controlling steady-state force and the rate of force production and shortening (reviewed in Reference 2). Much less work has been done to determine the processes controlling force production and shortening in cardiac muscle, although these are often assumed to be the same as for skeletal muscle. Although evidence from solution measurements suggests that the basic ATPase pathway in cardiac muscle is similar to that in skeletal muscle, 3-5 a detailed study of the chemomechanical cycle in skinned cardiac muscle is needed.
I
n both cardiac and skeletal muscles, contraction results from the cyclic interactions between actin and myosin when chemical energy, supplied by hydrolysis of MgATP, is converted into mechanical work, force, and shortening (chemomechanical transduction). Skeletal myosin and actomyosin ATPase activity have been studied extensively in solution, and a detailed picture of the number of steps and rate-limiting processes of the actomyosin ATPase cycle now exists (reviewed in Reference 1). More recently, similar analyses have been conducted in chemically skinned, fast skeletal muscle fibers using measurements of force transients that follow quick length changes; a variety of strong crossbridge inhibitors; or the photolysis of caged compounds such as ATP, ADP, P i , and Ca 2ϩ (reviewed in Reference 2). These studies are necessary to elucidate the chemomechanical transduction pathway, because the orderly array of thin and thick filaments in muscle imposes constraints on actomyosin interactions. The results of these studies have led to detailed models of chemomechanical transduction that suggest the rate-limiting processes controlling steady-state force and the rate of force production and shortening (reviewed in Reference 2). Much less work has been done to determine the processes controlling force production and shortening in cardiac muscle, although these are often assumed to be the same as for skeletal muscle. Although evidence from solution measurements suggests that the basic ATPase pathway in cardiac muscle is similar to that in skeletal muscle, [3] [4] [5] a detailed study of the chemomechanical cycle in skinned cardiac muscle is needed.
One particularly fruitful method of studying chemomechanical transduction in skeletal muscle has been to substitute analogs of ATP (NTPs) as the substrate for contraction. 6 -11 Correlation of the mechanical behavior using NTPs with changes in rate constants of actomyosin "state" transitions can provide useful information about mechanically and energetically important steps during the hydrolysis cycle. Recently, Regnier et al 10, 11 used a series of naturally occurring nucleotide analogs of ATP (NTPs) to study the kinetic regulation of the chemomechanical cycle in rabbit psoas muscle fibers. Most of these analogs bind more slowly to myosin, support less force and shortening, and have slower steady-state hydrolysis rates than when MgATP is the substrate for contraction. However, one of these analogs, 2-deoxy-ATP (dATP), uniquely had an affinity for myosin similar to that of ATP and increased both solution NTPase and rate of crossbridge cycling in psoas fibers. The rate of force development and fiber shortening velocity were also moderately increased by dATP with no effect on isometric force of muscle fibers during maximal Ca 2ϩ activation. Characterization of the posthydrolysis steps that control steady-state force and the kinetics of force generation in fibers led to the conclusion that dATP increases transition rates at both the beginning and the end of the crossbridge power stroke, resulting in a faster crossbridge cycling rate with no increase in number of strongly attached crossbridges contributing to steady-state force.
Because dATP is an effective substrate for fast skeletal myosin and is also rapidly rephosphorylated from dADP to dATP by creatine phosphokinase, 10 we chose to compare ATP with dATP as the contractile substrate to begin our studies of chemomechanical transduction in cardiac muscle. In this study, we compared ATP with dATP for cardiac trabeculae contractions, for solution NTPase measurements, and for in vitro motility studies with purified F-actin and HMM. Surprisingly, we found that dATP substantially increases the level of steady-state force and stiffness in skinned cardiac trabeculae containing either V1 or V3 myosin isoforms. This contrasts with our previous results in fast skeletal muscle and our current results in slow skeletal muscle. Further study showed that both the rate of tension redevelopment (k tr ) and the rate of crossbridge cycling in cardiac muscle are increased by dATP to a greater extent than in fast skeletal muscle fibers. Our results indicate that dATP may be a better contractile substrate than ATP in cardiac muscle and that the processes controlling maximal Ca 2ϩ -activated force development and shortening in cardiac muscle may differ from those in fast skeletal muscle. Preliminary reports of this work were published previously. 12, 13 
Materials and Methods

Mechanical Experiments
Male Sprague-Dawley rats (200 to 250 grams), either treated with propylthiouracil (PTU; 0.8% added to drinking water for 4 to 8 weeks) or untreated (as age-matched animals) were euthanized with sodium pentobarbital (50 mg/kg). Animal care and handling conformed to the National Institutes of Health policy on humane care and use of laboratory animals. Procedures were approved by the University of Washington Animal Care Committee. Hearts were excised, and the interior wall of the right ventricle was exposed to relaxing solution (see below) containing glycerol (50% vol:vol) and Triton X-100 (1%) overnight at 5°C. Individual trabeculae were dissected and stored at 5°C for up to 4 days. Glycerinated rabbit psoas and soleus fibers were prepared as previously described. 14 Trabeculae and skeletal fiber ends were wrapped in aluminum foil T-clips for attachment to a force transducer (either model 400A, 2.2-kHz resonant frequency [Cambridge Technology], or model AE801, Ն5-kHz resonant frequency [SensoNor] ) and a servo-motor (model 300, Cambridge Technology) tuned for a 300-s step response. Trabecular sarcomere length (L s ) was measured with helium-neon laser diffraction 15 and set to 2.25 m at pCa 9.2; skeletal fiber L s was set to 2.55 m. The following measurements were made as previously described: stiffness determined by sinusoidal length oscillations (500 Hz and 1000 Hz) and steady-state isometric force, 15 rate of isometric tension redevelopment (k tr ), 16 and unloaded shortening velocity (V u ) using the "slack-test" method. [15] [16] [17] Solutions contained (in mmol/L) phosphocreatine 15, EGTA 15, MOPS at least 40, free Mg 2ϩ 1, Na ϩ plus K ϩ 135, and DTT 1, and 250 U/mL creatine kinase (CK, Sigma), as well as either 5 mmol/L ATP or 5 mmol/L dATP (Sigma) at pH 7.0 and 15Ϯ1°C. Ionic strength was 0.2 mol/L. Affinity of dATP and ATP for Mg 2ϩ was assumed to be the same. 16 For activation solutions, the Ca 2ϩ level (expressed as pCa ϭϪlog [Ca 2ϩ ]) was set to pCa 4.5 or pCa 4.0 by adjusting Ca(propionate) 2 .
Solution Assays
Cardiac myosin was prepared from untreated and PTU-treated rat hearts by modification of previously reported methods. 18, 19 Heavy meromyosin (HMM) was obtained by 1-chloro-3-tosylamido-7-amino-2-heptanone-treated chymotryptic digestion of freshly prepared cardiac myosin, 20 stored on ice, and used within 2 days. Skeletal muscle myosin and HMM were prepared from rabbit back muscle as previously described. 21, 22 F-actin was prepared from rabbit back and leg muscle ether powder. 22, 23 ATPase and dATPase activities (NTPase) of cardiac HMM were measured at 21°C to 23°C using a colorimetric method as described. 21, 24 Maximum hydrolysis rate (V max ) and K m were estimated from increasing F-actin concentrations ([A]ϭ0 to 25 mol/L) for a single HMM preparation, using a hyperbolic fit to the data {yϭV max 
In Vitro Motility
Assays were carried out at 30°C using unregulated F-actin and analyzed as described, 22,24 -26 An expanded Materials and Methods section is available online at http://www.circresaha.org.
Results
Solution NTPase Activity
The steady-state hydrolytic activity (V HMM ) of cardiac HMM from PTU-treated rats was 40% lower than that from untreated rats (Table 1) . PTU treatment induces hypothyroidism, which causes myosin heavy chain (MHC) switching in the heart from predominantly ␣-MHC (V1) to ␤-MHC (V3). [27] [28] [29] [30] For both preparations, substituting ATP with dATP increased V HMM Ն65%. The rate of NTP hydrolysis by HMM was increased by F-actin and displayed saturation kinetics at high actin concentrations, allowing estimates of K m and V max ( Table 1 ). The V max (actin-activated) of normal HMM was increased Ͼ80-fold over V HMM (without actin) for both ATP and dATP, with a similar K m for F-actin concentration (Ϸ10 mol/L), and dATP increased V max by 53%. The increases in V HMM and V max , and similar K m for actin, resemble the effects of dATP on fast skeletal HMM. 10 
Mechanical Experiments
To determine how changing the hydrolytic activity of myosin influences the mechanical properties of cardiac muscle and to compare with our previous studies with fast skeletal muscle fibers, we measured maximum Ca 2ϩ -activated (pCa 4.0) steady-state force (F max ), the rate of tension redevelopment (k tr ), and the rate of unloaded shortening (V u ) in cardiac trabeculae from normal and PTU-treated rats. In chemically skinned trabeculae, F max was increased substantially with 5 mmol/L dATP compared with 5 mmol/L ATP. Figure 2A shows an example force record for a trabecula in which the contractile substrate was alternated between ATP and dATP. The trabecula was initially activated with ATP until a steady-state level of force was achieved; it was then transferred to a similar solution containing dATP, and force began to rise immediately. Once force leveled out, the trabecula was returned to the ATP solution, then again to the dATP, before being relaxed (pCa 9.2). This activation sequence demonstrates that the substantial increase in F max with dATP was rapidly and completely reversible. The increase in F max with dATP was consistent between preparations and occurred even when trabeculae were relaxed subsequent to activation with ATP. An example of this protocol is shown for a rabbit psoas fiber in Figure 2B and a rabbit soleus fiber in Figure 2C . These force records demonstrate that, in sharp contrast to trabeculae (panel A), dATP causes little or no increase in F max in fast skeletal fibers, as we have previously reported, 10, 11, 16 or in slow skeletal fibers. The results of several experiments are summarized in Table 2 . F max was increased by 41Ϯ4% with dATP in trabeculae from untreated rats and by 45Ϯ5% in trabeculae from PTU-treated rats. In comparison, there was no increase in F max with dATP in either psoas or soleus fibers. To determine whether the increase in trabecular F max with dATP resulted from an increase in the number of strongly bound crossbridges, we measured both force and stiffness in 4 trabeculae from untreated rats. For these trabeculae, F max was increased by 37Ϯ2%, and stiffness was increased proportionally by 35Ϯ2%, suggesting that, indeed, increases in F max resulted from an increase in the number of strongly bound crossbridges. In both psoas fibers 11 and soleus fibers, dATP had no effect on stiffness (data not shown), similar to the lack of effect on F max .
The increase in F max with dATP in cardiac muscle was accompanied by an increase in k tr of similar magnitude. The example k tr traces in Figure 3 show sequential activations in ATP, then dATP for trabeculae from one untreated rat ( Figure  3A ) and one PTU-treated rat ( Figure 3B ) and for a soleus fiber ( Figure 3C ). In these examples, F max was increased by 41% and 43%, whereas k tr was increased by 55% and 48% in the trabecula from the untreated and PTU-treated rats, respec- tively. In comparison, dATP increased F max by only 5% and approximately doubled k tr in the soleus fiber. The k tr data for all experiments are summarized in Table 2 . In trabeculae from PTU-treated rats, k tr was Ͼ2-fold slower than in trabeculae from untreated rats. With dATP, k tr was increased by 52% in trabeculae from untreated rats and by 38% in trabeculae from PTU-treated rats. An increase in k tr with dATP also occurs in both fast and slow skeletal muscle (without a concomitant increase in F max ), but to a lesser degree in psoas fibers (Table 2) . To determine whether dATP enhances sarcomere shortening as well as force production in cardiac muscle, we measured the unloaded shortening velocity (V u ) of trabeculae using the slack test (see Materials and Methods). Figure 4 shows "slack" times for 6 different length steps in an example trabecula, comparing activations with ATP versus dATP; the data for 6 trabeculae from untreated rats and 3 trabeculae from PTU-treated rats, with length steps ranging between 7% and 15%, are summarized in Table 2 (r  2 values for V u ranged from 0.83 to 0.99). V u was 3-fold slower for trabeculae from PTU-treated rats compared with trabeculae from untreated rats during activations with ATP, consistent with the difference in solution ATPase activities (Table 1) . dATP increased V u by an average of 74% in trabeculae from untreated rats and Ͼ2-fold in trabeculae from PTU-treated rats. These increases in V u with dATP were greater in magnitude than the increases in F max and k tr . The increased V u with dATP in cardiac muscle was similar to or greater than the effect of dATP in soleus fibers and at least 2-fold greater than the effect of dATP in fast skeletal muscle (Table 2) . 16 
In Vitro Motility
The greater increase in cardiac muscle V u with dATP (compared with fast skeletal muscle V u ) could result simply from the increased F max during contractions with dATP, especially considering the relatively large internal loads in cardiac muscle. 31 Therefore, an independent measure of F-actin sliding speed was determined using an in vitro motility assay. This method provides a simple system to study crossbridge cycling using purified F-actin and HMM, eliminating the potential effects of internal loads that occur in trabeculae. Measurements of rhodamine phalloidin F-actin sliding speed (V f ) at saturating [NTP] (1 to 3 mmol/L) gave results quantitatively similar to those found in trabeculae and fast skeletal fibers (Table 2) . V f with cardiac HMM from untreated rats was Ͼ2-fold faster than V f with cardiac HMM from PTU-treated rats. In both cases, dATP increased V f by 70%, similar to the increase found for V u . This compared with smaller, 30% increases by dATP in V f with skeletal HMM and V u in psoas fibers. When [NTP] was varied from 0.003 to 3 mmol/L, V f for HMM from normal rats was increased at all [NTPs] Ͼ30 mol/L, K app was unchanged, and V max was increased almost 2-fold by dATP ( Figure 5 ). The similar K app and much greater V f indicate that dATP binds to cardiac myosin with affinity similar to that of ATP, but it enhances cardiac filament sliding speed.
Discussion
The purpose of the present experiments was to determine whether the crossbridge transition rates controlling force and shortening in cardiac muscle are the same as in skeletal muscle. The major result from this study is that substitution of dATP for ATP as the contractile substrate reversibly increases maximal Ca 2ϩ -activated F max , stiffness, k tr , and V u in both untreated and PTU-treated rat cardiac muscle ( Table 2) . Measures of crossbridge cycling with purified cardiac HMM, ie, both acto-HMM NTPase and V f , were also increased by dATP (Tables 1 and 2 ). The rate of crossbridge cycling is also increased in rabbit psoas and soleus fibers, but without the increase in F max seen in cardiac muscle ( Table 2 ). The enhancement of F max in cardiac muscle was not due to accumulation of dADP, because previous control measurements have shown that CK rephosphorylates dADP to dATP and ADP to ATP with a similar time course 10 and, furthermore, k tr , V u , and V f were faster. The results of this study demonstrate that dATP markedly enhances the mechanical properties of cardiac muscle and suggest that the process limiting F max may differ in cardiac versus skeletal muscle.
PTU treatment decreased HMM NTPase, V u , V f , and k tr in cardiac muscle (Tables 1 and 2 ), which is indicative of an MHC isoform shift from V1 to V3, without changes in other contractile protein isoforms, that has previously been shown by others. [27] [28] [29] [30] In support of a V1-to-V3 isoform shift, V f using HMM from untreated versus PTU-treated rats in this study agrees well with V f measured using HMM from T4 versus PTU-treated rabbits. 32 Additionally, our measures of V u and k tr in cardiac and skeletal muscle agree with measurements made by others under similar conditions. [33] [34] [35] Finally, the magnitude reduction of k tr by PTU treatment in this study was similar to that for rat (primarily V1) versus guinea pig (primarily V3) cardiac trabeculae, 36 and k tr was similar for PTU-treated cardiac muscle, rabbit soleus fibers (Table 2) , and rat soleus fibers, 37 which also contain cardiac ␤-MHC. 38 Our observation that chronic PTU treatment slows rat cardiac muscle contractile mechanics is consistent with previous documented shifts in cardiac MHC isoforms (from ␣ to ␤). Importantly, the enhancement of contractile kinetics with dATP occurs regardless of myosin isoforms in both cardiac and skeletal muscle.
Mechanism of dATP Action
To identify the molecular basis for how dATP enhances the contractile kinetics of cardiac and skeletal muscle but enhances F max only in cardiac muscle, we first examined recent structural and sequence information. The amino acid residues that form the ATP binding pocket are conserved in all of the MHC sequences relevant to this study. 39 The 2Ј oxygen of ADP in the x-ray crystal structure of scallop myosin complexed with MgADP makes contact with 2 residues, Tyr126 and Arg128. 40 The residues equivalent to Tyr126 and Arg128 in the scallop sequence are conserved in rabbit skeletal MHC (Tyr129 and Trp131), rat cardiac ␣-MHC (Tyr127 and Trp129), and rat cardiac ␤-MHC (Tyr128 and Trp130). 39 Thus, existing structural information and sequence conservation offer no explanation for the different effects of dATP on F max in cardiac versus skeletal muscle, but are consistent with the enhancement of contractile kinetics in all of the preparations studied. This is evidenced by an enhancement of F max by dATP in trabeculae from PTU-treated rat heart, but not in soleus fibers, whereas k tr and V u are enhanced in both preparations that contain ␤-MHC (Table 2 ). A more general approach to explore the effect of dATP on contractile performance is to fit the data to kinetic models of the crossbridge cycle. The dATP-induced increase in skeletal muscle crossbridge cycling rate, with no concomitant change in F max , has been explained using the 2-state crossbridge model. 16 Figure 6 shows the 2-state model in which the rate constants for crossbridge attachment and force generation (transition from weak to strong binding states) and crossbridge detachment are lumped into the apparent rates f app and g app , respectively. During maximal Ca 2ϩ activation in fast psoas fibers, relatively small concomitant increases in both f app and g app could explain the lack of effect on F max [f app / (f app ϩg app )] and the slight increase in k tr ( f app ϩg app ) with dATP. 16 Our current results with soleus fibers can be explained by a similar mechanism. Because dATP increases F max in cardiac muscle, in addition to increasing k tr and V u (Table 2) , one possible explanation is that both f app and g app are increased (as in skeletal muscle), but f app is increased more than g app . Figure 6 predicts that a greater increase in f app (relative to increased g app ) should result in an increased number of strongly attached, cycling crossbridges. This prediction is supported by our observed proportional increase in trabecular stiffness and F max with dATP (see Results). A significant increase in crossbridge attachment and strong crossbridge binding with dATP, resulting from this kinetic mechanism, could increase the level of cardiac thin-filament activation, even at high levels of Ca 2ϩ . 2, 41 
Clinical Implications
The results of this study have potentially interesting implications for treating the force deficit associated with many cardiomyopathies. Our data thus far suggest that the enhancement of cardiac F max makes dATP an attractive candidate for specific improvement of cardiac function. Thus, ribonucleotide reductase, the enzyme responsible for conversion of ATP to dATP, 42 could be considered as a target for therapeutic treatment in heart failure, although the effects of upregulation of this enzyme on DNA synthesis and cellular metabolism need to be explored. Figure 6 . Scheme of 2-state model in which the rate constants for crossbridge attachment and force generation (transition from weak to strong binding states) and crossbridge detachment are lumped into the apparent rates f app and g app , respectively.
